mild Severity

Beech Pollen Allergy: A Mild Tree Pollen with Birch Cross-Reactivity

Beech pollen allergy is a mild, regionally limited tree pollen allergy primarily affecting patients in the northeastern United States and Europe. Beech trees are largely wind-pollinated and produce moderate amounts of pollen in spring, but clinical sensitization is far less common than to birch, oak, or grass. The major allergen Fag s 1 shares strong structural homology with Bet v 1, the major birch allergen, meaning most beech-sensitized patients are primarily birch-allergic. Symptoms are typical of tree pollen rhinoconjunctivitis and respond well to standard antihistamines and nasal corticosteroids.

mildPeak: Apr–MayUpdated July 13, 2026

Free Β· 5 min Β· Insurance accepted

Reviewed by Dr. Chet Tharpe, M.D.
As seen inUSA TODAYMen's HealthCBSForbes
The numbers
Headline stat
>0%
FAG S 1 HOMOLOGY TO BET V 1
US prevalence
<0%
Peak season
Apr–May
Symptoms tracked
0
Treatment paths
0
01Overview

What Is Beech Pollen Allergy?

Beech pollen allergy is a mild, regionally concentrated tree pollen allergy caused by IgE sensitization to pollen from trees in the Fagus genus, primarily the American beech (Fagus grandifolia) in the eastern United States and the European beech (Fagus sylvatica) across Europe.

Beech trees are monoecious and wind-pollinated, producing moderate amounts of airborne pollen in spring β€” but despite this, beech pollen is a relatively minor aeroallergen compared to birch, oak, and grass pollens that share the same spring bloom window.

The primary clinical significance of beech pollen lies in its molecular cross-reactivity with birch pollen. The major beech allergen, Fag s 1, is a pathogenesis-related protein 10 (PR-10) that shares over 70% amino acid sequence identity with Bet v 1, the major birch allergen. This means that most patients who test positive for beech pollen sensitization are actually birch-allergic individuals whose IgE antibodies cross-react with the structurally similar Fag s 1 protein. Primary beech sensitization β€” where beech is the dominant or sole sensitizing pollen β€” is uncommon in clinical practice. Understanding this birch-beech relationship is essential for accurate diagnosis and appropriate immunotherapy planning.

02Symptoms

Symptoms of Beech Pollen Allergy

Recognizing symptoms early helps you get the right treatment faster.

Sneezing

mild

Repetitive sneezing triggered by beech pollen inhalation, often worse during outdoor activities in April–May.

Nasal congestion

mild

Mucosal swelling from histamine release causes nasal blockage and pressure; may be worse in the morning when pollen counts peak.

Runny nose (rhinorrhea)

mild

Clear, watery nasal discharge is a hallmark of pollen-induced allergic rhinitis.

Itchy, watery eyes

mild

Allergic conjunctivitis with bilateral itch, tearing, and redness is common with tree pollen exposure.

Palate and throat itch

mild

Deep palatal or pharyngeal itch is characteristic of pollen allergy and helps distinguish allergic rhinitis from infectious rhinitis.

Oral allergy syndrome (PR-10 cross-reactivity)

mild

Lip tingling, mouth itch, and mild throat discomfort when eating raw apple, peach, cherry, or hazelnut β€” driven by PR-10 cross-reactivity between Fag s 1 and homologous food proteins.

When to see a doctor

Beech pollen allergy produces classic IgE-mediated rhinoconjunctivitis symptoms that are indistinguishable from other tree pollen allergies. The principal symptoms are sneezing, nasal congestion, clear rhinorrhea, nasal itch, and itchy, watery eyes. Because beech pollen grains are relatively large (35–45 micrometers), they deposit primarily in the upper airway β€” nasal mucosa and conjunctiva β€” rather than penetrating deeply into the bronchi. This upper-airway deposition pattern means that nasal and ocular symptoms dominate the clinical picture. For patients who are primarily birch-allergic with cross-reactive beech sensitization, symptoms during the April–May window reflect the combined birch-beech pollen burden. In mast years when beech pollen is abundant, birch-allergic patients may notice that their spring symptoms are more severe than expected from birch pollen counts alone β€” the additional beech pollen load contributes to the total allergen exposure. PR-10 proteins like Fag s 1 are heat-labile, meaning they are destroyed by cooking. Patients with birch-beech PR-10 sensitization may also experience oral allergy syndrome (tingling of the lips, mouth, and throat) when eating raw fruits and vegetables that contain homologous PR-10 proteins β€” particularly apple, peach, cherry, hazelnut, and carrot. If you experience throat tightness, difficulty breathing, or facial swelling, seek emergency care immediately.

Beech Pollen and Asthma Risk

Specific studies linking beech pollen to asthma exacerbations are lacking in the medical literature. However, the broader relationship between tree pollen allergy and asthma is well established: patients with allergic rhinitis have a substantially increased risk of developing asthma compared to non-atopic individuals, and tree pollen seasons are associated with increased asthma-related emergency department visits in sensitized populations. Because beech pollen grains are relatively large and deposit primarily in the upper airway, beech is less likely to trigger lower-airway asthma symptoms than smaller pollen grains from grasses or weeds. Patients with known asthma who notice worsening symptoms during the April–May tree pollen season in the northeastern US should discuss the full spring pollen panel β€” including birch, oak, maple, and beech β€” with their allergist to identify the relevant triggers.

If left untreated

Potential Complications of Beech Pollen Allergy

Untreated seasonal allergic rhinitis from any tree pollen, including beech, can lead to clinically significant complications over time. Chronic nasal inflammation impairs mucociliary clearance, creating conditions that favor secondary bacterial sinusitis β€” characterized by facial pain, thick discolored nasal discharge, and reduced sense of smell. The PR-10 cross-reactivity between Fag s 1 and Bet v 1 means that birch-allergic patients with beech co-sensitization may experience oral allergy syndrome with a range of raw fruits, vegetables, and tree nuts β€” typically mild and self-limiting, but occasionally distressing enough to cause dietary restriction. In mast years when beech pollen is abundant, birch-allergic patients may experience more severe spring symptoms than anticipated, potentially requiring escalation of pharmacotherapy. The masting behavior of beech trees β€” with dramatic year-to-year variation in pollen production β€” can make symptom patterns unpredictable and complicate treatment planning for sensitized patients.

Chronic sinusitis

Persistent nasal inflammation from untreated pollinosis can impair sinus drainage, leading to recurrent or chronic bacterial sinusitis.

Oral allergy syndrome

PR-10 cross-reactivity between Fag s 1 and homologous food proteins may cause oral tingling and lip swelling with raw apple, stone fruits, hazelnut, and carrot.

Unpredictable symptom severity

Beech masting behavior causes dramatic year-to-year variation in pollen counts, making spring symptom patterns harder to anticipate and manage.

03Why it happens

What Causes Beech Pollen Reactions?

Beech pollen reactions are caused by IgE antibodies that recognize proteins in beech pollen grains. The major allergen characterized to date is Fag s 1, a 17 kDa pathogenesis-related protein 10 (PR-10) from European beech (Fagus sylvatica). Fag s 1 is a Bet v 1 homolog β€” it shares the same three-dimensional protein fold and over 70% amino acid sequence identity with the major birch allergen Bet v 1. This structural similarity is the molecular basis for the extensive cross-reactivity observed between beech and birch pollen in clinical testing.

Common Species

American beech

Fagus grandifolia

European beech

Fagus sylvatica

Beech pollen allergy follows the classic Type I (IgE-mediated) hypersensitivity pathway. Fag s 1, a PR-10 protein, is recognized by specific IgE antibodies bound to the surface of mast cells and basophils. Upon re-exposure to beech pollen, Fag s 1 cross-links these IgE molecules, triggering mast cell degranulation with release of histamine, leukotrienes, and prostaglandins. These mediators produce the characteristic symptoms of allergic rhinoconjunctivitis: sneezing, nasal congestion, rhinorrhea, and ocular itch. Because Fag s 1 shares extensive structural homology with Bet v 1, the same IgE antibodies that recognize birch pollen can also bind Fag s 1 β€” meaning most beech pollen reactions are cross-reactive rather than primary sensitizations.

Because Bet v 1 is the dominant tree pollen allergen in northern temperate regions, the vast majority of patients who demonstrate IgE reactivity to beech pollen are primarily sensitized to birch. The beech reactivity represents cross-recognition of shared PR-10 epitopes rather than independent sensitization. True primary beech sensitization β€” where a patient is allergic to beech but not birch β€” is rare and has been documented primarily in regions where beech is the dominant forest tree and birch is relatively scarce.

Beech pollen grains are 35–45 micrometers in diameter, large enough to deposit in the upper airway, and are produced in moderate quantities during the spring flowering period. However, beech trees are inconsistent pollen producers β€” they exhibit masting behavior, with heavy pollen production in some years and very little in others, which contributes to the variable clinical significance of beech as an aeroallergen.

Who's most affected

Risk factors to watch for

01

Birch pollen sensitization

The dominant risk factor: over 70% amino acid sequence identity between Fag s 1 and Bet v 1 means most beech-positive patients are primarily birch-allergic.

02

Residence in northeastern US or northern Europe

American beech is concentrated in the Northeast and Great Lakes regions; European beech is widespread across central and northern Europe.

03

Personal or family history of atopy

A history of allergic rhinitis, asthma, or atopic dermatitis increases the probability of developing pollen sensitizations, including cross-reactive beech responses.

04

Occupational exposure in forestry or arboriculture

Forestry workers, arborists, and landscapers with prolonged close contact with beech trees during pollen season may have higher exposure intensity.

The Allergy Cascade

1.Exposure

Allergen contact

2.Detection

Immune recognition

3.IgE Response

Antibody production

4.Mast Cells

Histamine release

5.Symptoms

Allergic reaction

05Diagnosis

How to Diagnose Beech Pollen Allergy

Diagnosing beech pollen allergy requires both clinical context and standard allergy testing methodology. The first clinical question is whether the patient lives in or has visited the northeastern United States, Great Lakes region, or northern Europe during April–May β€” the only regions where beech pollen exposure is significant. Because beech pollen season overlaps almost completely with birch, oak, and maple, isolating beech-specific symptoms from the broader spring tree pollen burden is challenging without testing. Standard skin prick testing with a regional tree pollen panel that includes birch is the most practical first step. Because Fag s 1 shares over 70% sequence identity with Bet v 1, a positive birch test strongly suggests that any beech reactivity is cross-reactive. Specific IgE blood testing for birch (Bet v 1) and beech (Fag s 1) can confirm the molecular basis of sensitization, though beech-specific IgE assays are not routinely available in all US reference laboratories. At-home allergy testing services such as Curex provide panels covering 40+ environmental allergens with results typically within 5 days and insurance coverage often available, allowing patients in the Northeast to map their spring pollen sensitization landscape β€” including birch, oak, maple, and grass pollens that are typically the primary drivers of symptoms. A board-certified allergist can then interpret results in the context of local pollen calendars and the known birch-beech cross-reactivity relationship.

Skin prick test with regional tree pollen panel

A standard tree pollen SPT panel including birch, oak, maple, and beech (where available) can identify sensitizations. A positive birch test with or without beech positivity strongly suggests PR-10 cross-reactivity as the mechanism.

Specific IgE blood testing (serology)

Serology can measure IgE to birch (Bet v 1) and, where available, beech (Fag s 1). Molecular component testing for Bet v 1 confirms PR-10 sensitization, which explains cross-reactive beech responses.

Nasal provocation test

Research settings can administer controlled doses of beech pollen extract intranasally and measure symptom scores; used primarily in clinical research, not routine practice.

At-home testing

Test from home with Curex

Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.

Take the allergy quiz
Insurance acceptedBoard-certified allergists
06Treatment

Treatment Options for Beech Pollen Allergy

See how different approaches stack up for managing your allergy symptoms long-term.

Treatment for beech pollen allergy follows the same evidence-based principles used for any tree pollen rhinoconjunctivitis. The foundation is pharmacotherapy to control symptoms during the April–May pollen season, combined with practical avoidance strategies. For patients with confirmed birch sensitization and moderate-to-severe spring symptoms, allergen immunotherapy targeting birch (Bet v 1) is the most logical approach β€” because beech reactivity is almost always cross-reactive, birch immunotherapy may provide benefit for beech-related symptoms as well.

Because beech pollen is a minor aeroallergen and no standardized beech extract is widely available in the US, immunotherapy is directed at the primary sensitizer (birch) rather than beech specifically. The strong PR-10 homology between Fag s 1 and Bet v 1 provides a molecular rationale for this approach: desensitization to Bet v 1 should reduce IgE responses to cross-reactive PR-10 proteins, including Fag s 1.

Patients should also be counseled on the oral allergy syndrome associated with PR-10 sensitization: raw apple, stone fruits, hazelnut, and carrot may cause oral tingling during the pollen season, and cooking these foods typically eliminates the reaction.

Avoidance during peak bloom

Minimizing outdoor exposure during April–May when beech pollen counts peak β€” keeping windows closed, using air conditioning, and showering after outdoor activities β€” reduces pollen load.

Not applicable

Partial symptom reduction; complete avoidance is impractical during spring

Second-generation oral antihistamines

Non-sedating H1 antihistamines reduce sneezing, itch, and eye symptoms; taken daily at the start of pollen season for best effect.

Zyrtec (cetirizine), Claritin (loratadine), Allegra (fexofenadine), Xyzal (levocetirizine)

Studies show 50–60% reduction in rhinitis symptom scores

Intranasal corticosteroids

First-line therapy for allergic rhinitis; reduce mucosal inflammation, congestion, and itch more effectively than antihistamines alone for persistent symptoms.

Flonase (fluticasone), Nasonex (mometasone), Nasacort (triamcinolone), Rhinocort (budesonide)

Meta-analyses demonstrate 30–40% greater symptom reduction vs antihistamine monotherapy

Antihistamine eye drops

Topical ophthalmic antihistamines rapidly relieve allergic conjunctivitis symptoms independent of oral medication.

Pataday (olopatadine), Alaway (ketotifen), Lastacaft (alcaftadine)

Evidence shows fast onset (within minutes) and effective itch/redness control

Allergen immunotherapy (birch-focused)

For confirmed birch sensitization (which captures beech via Bet v 1/Fag s 1 cross-reactivity), sublingual or subcutaneous immunotherapy with birch extract can provide long-term desensitization.

Standardized birch allergen extracts (Bet v 1-containing)

Clinical trials in birch-sensitized populations show 60–80% symptom reduction with immunotherapy

Traditional

  • NoTreats root cause
  • NoLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • YesLow side effects
  • PartialEstimated cost

Allergy Shots (SCIT)

  • YesTreats root cause
  • YesLong-lasting relief
  • NoAt-home treatment
  • NoNo office visits
  • PartialLow side effects
  • PartialEstimated cost

Immunotherapy (SLIT)

Recommended
  • YesTreats root cause
  • YesLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • YesLow side effects
  • YesEstimated cost
Immunotherapy

Immunotherapy for Beech Pollen Sensitization

Instead of masking symptoms, immunotherapy retrains your immune system.

If you have been managing spring tree pollen symptoms with antihistamines and nasal sprays but still struggle each April and May, immunotherapy may offer a more durable solution. The immunotherapy strategy for beech pollen is built on the molecular relationship between beech and birch: because Fag s 1 shares over 70% sequence identity with Bet v 1, most beech-sensitized patients are primarily birch-allergic, and birch immunotherapy is the logical therapeutic target. Birch pollen extracts are well-standardized and widely available for both subcutaneous immunotherapy (allergy shots) and sublingual immunotherapy (allergy drops). Clinical trials in birch-sensitized populations demonstrate 60–80% reduction in seasonal rhinoconjunctivitis symptoms, and the cross-reactivity between Bet v 1 and Fag s 1 means that birch immunotherapy may reduce beech-related symptoms as well β€” though direct evidence for this cross-protection is limited. A board-certified allergist with access to component-resolved diagnostics can confirm whether Bet v 1 is the primary sensitizer and whether birch immunotherapy is appropriate. Sublingual immunotherapy drops, available through providers like Curex with plan-specific pricing (https://getcurex.com/learn/curex-pricing), allow patients to undergo desensitization at home without weekly clinic visits, and plans are typically covered by most insurance. In a real-world Curex study of 2,897 patients on at-home sublingual immunotherapy (Tharpe et al., Frontiers in Allergy, 2026), clinically meaningful symptom improvement rose to 45% of patients by two years, quality-of-life improvement reached 90.7%, and adherence exceeded 90% with no anaphylaxis reported. This is particularly practical for Northeast patients managing overlapping birch, oak, and maple pollen seasons.

1Step 1

Confirm birch sensitization

Skin prick testing or specific IgE blood testing for birch (Bet v 1) establishes whether beech reactivity is cross-reactive β€” the most common scenario.

2Step 2

Component-resolved diagnostics

If available, molecular testing for Bet v 1 confirms PR-10-driven sensitization and clarifies the immunotherapy target.

3Step 3

Custom immunotherapy formulation

Allergen drops or shots are formulated based on the confirmed birch sensitization profile, with the expectation of cross-protection for beech via shared PR-10 epitopes.

4Step 4

3–5 year desensitization course

Gradually increasing allergen doses build immune tolerance; most patients experience significant improvement within 6–12 months.

β€œClinical trials in birch-sensitized populations show 60–80% reduction in seasonal rhinoconjunctivitis symptoms with allergen immunotherapy”

Curex drops

Not sure which spring pollen is triggering your allergies?

Curex's free allergy quiz checks tree pollens and dozens of other common allergens, then connects you to at-home testing and treatment if you qualify.

  • MD-led
    Board-certified allergists
  • Plan-specific
    Pricing Β· Confirm your quote
  • 50K+
    Patients treated
  • HSA/FSA
    Eligible
Living with it

Living With Beech Pollen Sensitivity

Managing beech pollen sensitivity is straightforward once the birch-beech cross-reactivity relationship is understood. The most important first step is confirming that birch is the primary sensitizer β€” because beech reactivity is almost always cross-reactive, treating birch allergy effectively addresses beech symptoms as well. A complete spring tree pollen panel through an allergist reveals the full sensitization profile and enables targeted treatment. For patients in the northeastern United States, the April–May window is the critical period. Creating a symptom diary during this time helps document which days are worst and correlates with local pollen count data for birch, oak, maple, and beech. This information is invaluable for an allergist designing an immunotherapy protocol. Because beech trees exhibit masting behavior, patients may notice that some springs are much worse than others β€” this is normal and reflects the dramatic year-to-year variation in beech pollen production. In mast years, birch-allergic patients may need to escalate their pharmacotherapy temporarily to manage the additional beech pollen burden.

  • Identify birch as the primary trigger

    Because Fag s 1 shares over 70% sequence identity with Bet v 1, most beech-sensitized patients are primarily birch-allergic. Treating birch allergy is the most effective strategy for managing beech-related symptoms.

  • Map your full spring sensitization profile

    A complete tree pollen panel including birch, oak, maple, and beech reveals the full picture. Most Northeast patients are sensitized to multiple spring trees, and immunotherapy can target the dominant allergens.

  • Plan around the April–May window

    Pre-treating with nasal steroids, planning outdoor activities around low-count hours, and using HEPA filtration indoors makes the spring pollen season manageable even in mast years.

When Does Beech Pollen Peak?

Beech pollen season is relatively brief and occurs in mid-spring, typically April through May in the northeastern United States and at similar latitudes in Europe. The exact timing varies by latitude and elevation: beech trees at higher elevations or more northern latitudes may pollinate later into May, while those in warmer southern portions of their range may begin in late March. Beech trees exhibit masting behavior β€” a reproductive strategy where trees in a region synchronize heavy seed and pollen production in some years (mast years) and produce very little in others. This means that beech pollen counts can vary dramatically from year to year, with mast years producing 10–100 times more pollen than non-mast years. This variability makes beech an inconsistent aeroallergen: in a low-pollen year, even sensitized patients may have minimal symptoms, while a mast year can produce noticeable symptoms in birch-allergic patients who cross-react to beech. Because beech pollen season overlaps almost completely with birch, oak, and maple pollen seasons in the same regions, isolating beech-specific symptoms from the broader spring tree pollen burden is clinically challenging without specific IgE testing.

Spring

April - May

medium intensity

Late Spring

Late May - Early June

low intensity

Preventing Beech Pollen Reactions

Preventing beech pollen reactions combines practical environmental controls with proactive medical management. During April–May in the northeastern United States β€” the peak beech pollen period β€” staying indoors during mid-morning hours when tree pollen counts peak, keeping windows and doors closed, and using air conditioning with HEPA filtration significantly reduces indoor pollen burden. After any outdoor activity during the spring pollen season, showering and changing clothes removes pollen trapped in hair and on clothing that would otherwise continue to cause exposure indoors. Wearing wraparound sunglasses outdoors reduces pollen contact with the conjunctiva. Because beech pollen production varies dramatically between mast and non-mast years, patients should monitor local pollen counts through the National Allergy Bureau or weather apps to identify high-count days. Starting antihistamines or intranasal corticosteroids 1–2 weeks before the expected April bloom reduces the severity of the initial inflammatory response. For patients with known birch-beech cross-reactivity, managing birch exposure is the priority β€” beech pollen reduction is a secondary benefit of the same environmental controls.

Monitor local pollen counts

Use the National Allergy Bureau or weather app pollen tracking to identify high-count days during April–May and proactively limit outdoor exposure.

Keep windows closed in peak bloom

Close windows and use air conditioning with HEPA filtration during April–May in the northeastern US and Great Lakes region.

Shower after outdoor exposure

Showering and changing clothes after time outdoors removes pollen from hair, skin, and clothing that would continue causing indoor exposure.

Pre-season medication start

Beginning intranasal corticosteroids 1–2 weeks before the expected April beech bloom reduces the initial inflammatory response and controls symptoms more effectively.

Manage birch as the primary trigger

Because beech reactivity is almost always cross-reactive with birch, controlling birch pollen exposure is the most effective prevention strategy.

Long-term outlook

Outlook for Beech Pollen Allergy

The prognosis for beech pollen allergy is generally favorable. Because beech is a minor aeroallergen and most beech reactivity is cross-reactive with birch, patients who manage their birch allergy effectively typically experience adequate control of beech-related symptoms as well. Standard pharmacotherapy β€” antihistamines, intranasal corticosteroids, and eye drops β€” provides good symptom control for the April–May season. For patients pursuing allergen immunotherapy targeting birch (Bet v 1), clinical trials demonstrate 60–80% long-term symptom reduction. The strong PR-10 homology between Fag s 1 and Bet v 1 provides a molecular rationale for cross-protection, though direct evidence for beech-specific benefit from birch immunotherapy is limited. The masting behavior of beech trees means that symptom severity will vary from year to year, but this variability is manageable with flexible pharmacotherapy and environmental controls.

What to expect

Key takeaways

01

Beech pollen allergy is mild and regionally limited to the northeastern US and northern Europe; it is not a nationwide concern

02

Over 70% amino acid sequence identity between Fag s 1 and Bet v 1 means most beech-sensitized patients are primarily birch-allergic

03

Beech masting behavior causes dramatic year-to-year variation in pollen production, making symptom patterns unpredictable

04

Birch immunotherapy may provide cross-protection for beech via shared PR-10 molecular epitopes

Diet

Diet and Beech Pollen Cross-Reactivity

Dietary cross-reactivity is a consideration for beech pollen allergy because the major allergen Fag s 1 is a PR-10 protein β€” the same protein family as Bet v 1, the major birch allergen. PR-10 proteins are heat-labile and found in a wide range of raw plant foods. Patients with birch-beech PR-10 sensitization may experience oral allergy syndrome (tingling of the lips, mouth, and throat) when eating raw apple, peach, cherry, pear, hazelnut, almond, carrot, celery, and soy. These symptoms are typically mild and self-limiting, resolving within 15–30 minutes without treatment. Cooking destroys PR-10 proteins, so cooked, baked, or canned versions of the same foods are usually well-tolerated. The clinical significance of PR-10 food cross-reactivity is individually variable and should be discussed with an allergist.

Foods to limit

  • Raw apple (PR-10-sensitized patients only)

    PR-10 cross-reactivity between Fag s 1/Bet v 1 and Mal d 1 may cause oral tingling; cooked apple is typically tolerated.

  • Raw stone fruits (PR-10-sensitized patients only)

    Peach, cherry, and plum contain PR-10 proteins that cross-react with birch and beech pollen allergens; cooking denatures the proteins.

  • Raw hazelnut (PR-10-sensitized patients only)

    Hazelnut PR-10 protein (Cor a 1) shares structural homology with Fag s 1 and Bet v 1; roasted hazelnuts are often tolerated.

FAQ

Frequently Asked Questions

Not exactly the same, but they are closely related at the molecular level. The major beech allergen, Fag s 1, shares over 70% amino acid sequence identity with Bet v 1, the major birch allergen. Both are PR-10 proteins with nearly identical three-dimensional structures. This means most patients who test positive for beech pollen are actually birch-allergic individuals whose IgE antibodies cross-react with the structurally similar Fag s 1 protein.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.

Get started today

Ready to treat your Beech Pollen allergies for good?

Get a personalized treatment plan from board-certified allergists, delivered to your door.

Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.

Compare Curex plan pricing
3-minute quizBoard-certified allergistsProgram-specific pricing Β· Confirm your written quote

Questions about Curex itself?

Straight answers about the company, the evidence, what patients report, and what it costs β€” including the parts that are not flattering.

Think a tree pollen like beech or birch is behind your symptoms?

Curex's free allergy quiz checks tree pollens and dozens of other common allergens, then connects you to at-home testing and treatment if you qualify.

Take the free allergy quiz

Ready to treat your allergies at the source?

Take the free allergy quiz to find out if immunotherapy is right for you and get started with personalized treatment today.

Take Free Allergy Quiz